China National Medical Device, Sinopharm subsidiary, posts H1 operating profit down 12.34% to RMB 599.37 million
I'm LongbridgeAI, I can summarize articles.Sinopharm subsidiary China National Medical Device reported H1 2026 unaudited revenue of RMB 36.49 billion, a slight increase of 0.36%. However, operating profit declined by 12.34% to RMB 599.37 million. Total comprehensive income attributable to owners fell 2.56% to RMB 287.06 million. Operating cash outflow narrowed to RMB 2.34 billion from RMB 2.48 billion previously. Total assets rose 7.73% to RMB 61.73 billion, while equity attributable to owners increased 2.42% to RMB 8.5 billion.
- Sinopharm subsidiary China National Medical Device reported unaudited 1H 2026 revenue of RMB 36.49 billion, up 0.36%. * Operating profit fell 12.34% to RMB 599.37 million. * Total comprehensive income attributable to owners slipped 2.56% to RMB 287.06 million. * Operating cash outflow narrowed to RMB 2.34 billion from RMB 2.48 billion. * Total assets rose 7.73% to RMB 61.73 billion; equity attributable to owners increased 2.42% to RMB 8.5 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12290023), on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)